Tudor Investment Corp ET AL Makes New $822,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Tudor Investment Corp ET AL purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 32,545 shares of the biopharmaceutical company's stock, valued at approximately $822,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Barclays PLC grew its holdings in Celldex Therapeutics by 140.7% in the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock valued at $4,431,000 after purchasing an additional 76,207 shares during the period. Mirador Capital Partners LP grew its stake in shares of Celldex Therapeutics by 2.9% during the 4th quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company's stock valued at $3,020,000 after buying an additional 3,345 shares during the period. SG Americas Securities LLC increased its holdings in shares of Celldex Therapeutics by 24.4% during the 4th quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after buying an additional 4,967 shares during the last quarter. KBC Group NV raised its position in shares of Celldex Therapeutics by 79.1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares during the period. Finally, Sovran Advisors LLC purchased a new position in shares of Celldex Therapeutics in the 4th quarter worth $2,867,000.

Analyst Ratings Changes

Several brokerages have commented on CLDX. UBS Group dropped their price target on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 price objective for the company. The Goldman Sachs Group cut their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday. Finally, Morgan Stanley decreased their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX traded down $1.19 during trading on Friday, hitting $18.33. The company's stock had a trading volume of 1,001,538 shares, compared to its average volume of 889,846. The company has a market capitalization of $1.22 billion, a PE ratio of -7.13 and a beta of 1.39. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The stock's 50-day moving average price is $18.99 and its two-hundred day moving average price is $22.84.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.